EMA RESPONDS TO CRITICS OVER CLINICAL TRIAL RESULTS TRANSPARENCY
July 1st, 2011
BY KEITH NUTHALL
THE EUROPEAN Medicines Agency (EMA) will allow public access to its databases with information on the potential side effects of medicines. Its announcement follows criticism that EMA has been too secretive with such data. In a communiqué, the agency said it would henceforth produce monthly reports summarising information held in its EudraVigilance database for all medicines with central EMA authorisation. And it will provide searchable reports for all medicines by the end of 2012. Meanwhile, EMA would further improve the search and data-output ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.